Surgical treatment in synchronous esophageal cancers - a systematic review on survival outcomes
A partir d'une revue systématique de la littérature (34 articles), cette étude fait le point sur le traitement chirurgical de tumeurs synchrones de l'oesophage
Objective: It is crucial to consider that other primary cancers may co-occur with synchronous oesophageal cancers when evaluating and deciding on treatment. This research aimed to assess available information on the viability and safety of synchronous resection of oesophageal carcinomas.
Methods: A systematic literature search was conducted on PubMed, Scopus, Cochrane Central Register of Controlled Trials, and EMBASE to identify 34 peer-reviewed articles up to 2025. It included randomised controlled trials (RCTs), controlled clinical trials, observational studies, cohort studies, and case-control studies with adult patients (
≥
18 years) undergoing surgery.
Results: Studies on the surgical management of oesophageal cancer metastasis revealed that the median overall survival within 1 to 3 years ranged from 21.% % to 32%. In one study, the 5-year median survival was 38.8% in TTE and 23% in esophagectomy plus gastrectomy. Regarding data on case series, concomitant stomach and oesophageal neoplasms were present in 89 patients (76% of the overall group). Seventy-five patients had adenocarcinomas, whereas the remaining 10 patients had gastrointestinal stromal tumours (GISTs). Eighty-seven patients had a transthoracic echocardiogram (TTE), one patient had a transhiatal esophagectomy (THE), and one patient had a thoracoabdominal approach. The remaining 59 patients had gastrectomies that left some stomach tissue intact. In 93% of the patients, the second primary tumour could be diagnosed prior to surgery.
Conclusion: Concurrent resection of oesophageal and other primary solid organ cancers is safe, technically possible, and linked to acceptable perioperative death rates on an individual basis.
European Journal of Surgical Oncology , article en libre accès, 2025